{{Drugbox
| IUPAC_name        = [7-(1''H''-Imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydro-1(2''H'')-quinoxalinyl]acetic acid
| image             = Zonampanel.svg
| alt               = Skeletal formula
| width             = 200
| image2            = Zonampanel molecule spacefill.png 
| alt2              = Space-filling model of zonampanel
| CAS_number        = 210245-80-0
| ATC_prefix        = None
| ATC_suffix        = 
| PubChem           = 148200
| DrugBank          = 
| ChemSpiderID      = 130649
| C=13 | H=9 | N=5 | O=6
| molecular_weight  = 331.241 g/mol
| smiles            = c1cn(cn1)c2cc3c(cc2[N+](=O)[O-])[nH]c(=O)c(=O)n3CC(=O)O
| StdInChI          = 1S/C13H9N5O6/c19-11(20)5-17-8-4-9(16-2-1-14-6-16)10(18(23)24)3-7(8)15-12(21)13(17)22/h1-4,6H,5H2,(H,15,21)(H,19,20)
| StdInChIKey       = SPXYHZRWPRQLNS-UHFFFAOYSA-N
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
}}

'''Zonampanel''' ([[International Nonproprietary Name|INN]], code name '''YM872''') is a [[quinoxalinedione]] [[chemical derivative|derivative]] [[drug]] and [[competitive antagonist]] of the [[AMPA receptor]] which was being investigated by [[Yamanouchi]]/[[Astellas Pharma]] as a [[neuroprotective drug]] for the treatment of [[ischemic stroke]] but never completed [[clinical trial]]s.<ref name="Jain2011">{{cite book|author=Kewal K. Jain|title=The Handbook of Neuroprotection|url=https://books.google.com/books?id=PGZ3Qqvjmo0C&pg=PA154|date=14 February 2011|publisher=Springer Science & Business Media|isbn=978-1-61779-049-2|pages=154–}}</ref><ref name="Gulati2007">{{cite book|author=Arunabha Ray, Kavita Gulati|title=Current Trends in Pharmacology|url=https://books.google.com/books?id=uB2vWIQBbxoC&pg=PA321|date=1 January 2007|publisher=I. K. International Pvt Ltd|isbn=978-81-88237-77-7|pages=321–}}</ref><ref name="Waxman2005">{{cite book|author=Stephen Waxman|title=Multiple Sclerosis As A Neuronal Disease|url=https://books.google.com/books?id=Eeqy733NZSEC&pg=PA245|date=27 May 2005|publisher=Academic Press|isbn=978-0-08-048941-4|pages=245–}}</ref><ref name="GillPulido2007">{{cite book|author1=Santokh Gill|author2=Olga Pulido|title=Glutamate Receptors in Peripheral Tissue: Excitatory Transmission Outside the CNS|url=https://books.google.com/books?id=wcjiZ58mypIC&pg=PA37|date=31 January 2007|publisher=Springer Science & Business Media|isbn=978-0-306-48644-9|pages=37–}}</ref> In clinical trials, zonampanel produced severe [[side effect]]s including [[hallucination]]s, [[Psychomotor agitation|agitation]], and [[catatonia]] in patients, resulting in early termination of the trials.<ref name="Farooqui2010">{{cite book|author=Akhlaq A. Farooqui|title=Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases|url=https://books.google.com/books?id=q_G5aon0WbAC&pg=PA73|date=2 September 2010|publisher=Springer Science & Business Media|isbn=978-1-4419-6652-0|pages=73–}}</ref>

==References==
{{Reflist}}


{{Ionotropic glutamate receptor modulators}}

[[Category:AMPA receptor antagonists]]
[[Category:Imidazoles]]
[[Category:Neuroprotective agents]]
[[Category:Nitro compounds]]
[[Category:Quinoxalines]]
[[Category:Astellas Pharma]]
[[Category:Acetic acids]]


{{nervous-system-drug-stub}}